Structural Formula (Image 01)
Alvesco Aerosol, Metered
Product Images NDC 70515-711
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Alvesco (NDC 70515-711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Covis Pharma Us, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Image 02)
This appears to be a table showcasing the mean change in FEV (Forced Expiratory Volume) from baseline, prior to the morning dose, for different treatment groups over the course of a few weeks. The table mentions different treatments including Placebo, Avesco 160 ug once daily and Avesco 80 ug twice daily, with the last row possibly indicating a change in treatment.*
Figure 2 (Image 03)
Figure 3 (Image 04)
This is a chart displaying the mean change in FEV1 (forced expiratory volume in one second) in liters. The change from baseline is measured prior to the AM (morning) dose. It shows the results over a 12-week period for a placebo group, a group taking Avesco at 320 micrograms per day, and a group taking Avesco at 640 micrograms per day. The chart includes statistical information indicating that the differences between the Avesco groups and the placebo group are statistically significant at a p-value of less than 0.05.*
Figure A (Image 05)
Figure B (Image 06)
Figure C (Image 07)
Figure D (Image 08)
Figure E (Image 09)
Figure F (Image 10)
Figure G (Image 11)
Figure H (Image 12)
Figure I (Image 13)
Principal Display Panel (80 mcg Carton)
This appears to be the product information of ALVESCO® Inhalation Aerosol containing 80 mcg/actuation of ciclesonide. Each canister is 6.1g and contains a solution of ciclesonide in propellant HFA-134a (1,112 tetrafluoroethane). It is used for oral inhalation and comes with Patient's Instructions. It should be kept at room temperature between 15-30°C and away from children to avoid spraying in eyes. The package insert should be consulted for dosage information. The rest of the text is either unreadable or consists of product codes and numbers.*
Principal Display Panel (160 mcg Carton)
This is a description of the medication Alvesco, which comes in a 6.1 canister and contains a solution of ciclesonide and propellant HFA-134a. The inhaler delivers 200 mg from the valve and 160 mg of ciclesonide from the actuator. The dosage and administration instructions can be found in the package insert. The medication should be stored between 15-30°C and precautions should be taken to avoid exposure to heat or flame. The canister should not be punctured and should be kept out of reach of children. Avoid spraying in eyes. The medication is Rx only and is manufactured for Covis Pharma in Switzerland. There is also a lot and an expiration date provided.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
